Nebula Research & Development LLC Invests $432,000 in DaVita Inc. (NYSE:DVA)

Nebula Research & Development LLC purchased a new position in DaVita Inc. (NYSE:DVA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,886 shares of the company’s stock, valued at approximately $432,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DVA. Kovitz Investment Group Partners LLC acquired a new position in shares of DaVita during the 4th quarter worth approximately $322,000. Coppell Advisory Solutions LLC grew its holdings in DaVita by 50.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after buying an additional 100 shares in the last quarter. MGO One Seven LLC increased its stake in shares of DaVita by 20.0% in the 4th quarter. MGO One Seven LLC now owns 2,337 shares of the company’s stock worth $350,000 after acquiring an additional 390 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of DaVita by 110.5% during the 4th quarter. Hsbc Holdings PLC now owns 153,838 shares of the company’s stock worth $23,012,000 after acquiring an additional 80,750 shares during the period. Finally, Stifel Financial Corp boosted its position in shares of DaVita by 3.2% during the 4th quarter. Stifel Financial Corp now owns 5,937 shares of the company’s stock valued at $888,000 after acquiring an additional 185 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on DVA shares. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Barclays upped their price objective on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. StockNews.com raised DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Finally, Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $166.33.

DaVita Stock Up 0.7 %

NYSE:DVA opened at $141.45 on Wednesday. DaVita Inc. has a 52 week low of $131.27 and a 52 week high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock’s fifty day moving average is $146.13 and its two-hundred day moving average is $155.01. The stock has a market capitalization of $11.32 billion, a price-to-earnings ratio of 13.17, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.